TOVX Earnings Theriva Biologics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -0.05 | 2026-05-05 | 10-Q |
| FY 2025 | 2025-12-31 | -2.08 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -3.38 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | -3.64 | 2025-08-11 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.55 | 2026-05-05 | 10-Q |
| FY 2025 | 2024-12-31 | -19.03 | 2026-03-12 | 10-K |
| Q3 2025 | 2024-09-30 | -24.47 | 2025-11-12 | 10-Q |
| Q2 2025 | 2024-06-30 | -18.45 | 2025-08-11 | 10-Q |
| Q1 2025 | 2024-03-31 | -7.53 | 2025-05-14 | 10-Q |
| FY 2024 | 2023-12-31 | -28.48 | 2025-03-06 | 10-K |
| Q3 2024 | 2023-09-30 | -20.38 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.63 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.30 | 2024-05-07 | 10-Q |
| FY 2023 | 2022-12-31 | -1.31 | 2024-03-25 | 10-K |
| Q3 2023 | 2022-09-30 | -0.87 | 2023-11-13 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.59 | 2023-08-08 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.31 | 2023-05-11 | 10-Q |
| FY 2022 | 2021-12-31 | -1.90 | 2023-03-30 | 10-K |
| Q3 2022 | 2021-09-30 | -1.51 | 2022-11-10 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.31 | 2022-08-11 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.